Processing

Please wait...

Settings

Settings

Goto Application

1. EP1829879 - Amino pyrimidine compounds for the treatment of inflammatory disorders

Office
European Patent Office
Application Number 06101510
Application Date 10.02.2006
Publication Number 1829879
Publication Date 05.09.2007
Publication Kind A1
IPC
C07D 491/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
CPC
C07D 491/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
Applicants CELLZOME UK LTD
Inventors REID ALISON
WILSON FRANCIS
DYKE HAZEL
PRICE STEVEN
CRAMP SUE
Designated States
Title
(DE) Amino Pyrimidine Verbindungen zur Behandlung von entzündlichen Erkrankungen
(EN) Amino pyrimidine compounds for the treatment of inflammatory disorders
(FR) Dérivés de amino pyrimidine pour le traitment des maladies inflammatoires
Abstract
(EN) The present invention relates to novel amino pyrimidine compounds having the general formula (I) for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds.